Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$4,457 Mln
P/E Ratio
--
P/B Ratio
12.87
Industry P/E
--
Debt to Equity
0
ROE
-0.15 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.67
CFO
$-248.18 Mln
EBITDA
$-335.14 Mln
Net Profit
$-324.34 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Alpine Immune Sciences (ALPN)
| 240.87 | 0.65 | 107.84 | 583.89 | 62.90 | 61.30 | -- |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Alpine Immune Sciences (ALPN)
| 159.32 | -46.93 | 9.92 | 228.13 | 4.35 | -66.94 | 25.00 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1.97 | 27.14 | -- | -250 |
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The... company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated. Read more
Executive Chairman & CEO
Dr. Mitchell H. Gold M.D.
Executive Chairman & CEO
Dr. Mitchell H. Gold M.D.
Headquarters
Seattle, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Alpine Immune Sciences Inc (ALPN) stood at $ 406 Mln as on 31-Mar-24
The share price of Alpine Immune Sciences Inc (ALPN) is $64.97 (NASDAQ) as of 20-May-2024 09:30 EDT. Alpine Immune Sciences Inc (ALPN) has given a return of 62.9% in the last 3 years.
Alpine Immune Sciences Inc (ALPN) has a market capitalisation of $ 4,457 Mln as on 05-Aug-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Alpine Immune Sciences Inc (ALPN) is 12.87 times as on 05-Aug-2024, a 460% premium to its peers’ median range of 2.30 times.
Since, TTM earnings of Alpine Immune Sciences Inc (ALPN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alpine Immune Sciences Inc (ALPN) and enter the required number of quantities and click on buy to purchase the shares of Alpine Immune Sciences Inc (ALPN).
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
The CEO & director of Dr. Mitchell H. Gold M.D.. is Alpine Immune Sciences Inc (ALPN), and CFO & Sr. VP is Dr. Mitchell H. Gold M.D..
There is no promoter pledging in Alpine Immune Sciences Inc (ALPN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
3
|
| Alpine Immune Sciences Inc. (ALPN) | Ratios |
|---|---|
|
Return on equity(%)
|
-14.9
|
|
Operating margin(%)
|
-81.38
|
|
Net Margin(%)
|
-62.38
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Alpine Immune Sciences Inc (ALPN) was $-13 Mln.
